Hospitals
Training
Courses
Training Plan
Training
Collaborate

Inflammatory Bowel Disease (IBODI)

INFECTION, IMMUNITY AND ENVIRONMENT
STEM CELLS IMMUNOLOGY MICROBIOTA CROHN'S DISEASE
TARGETS

Our objective is to understand the pathophysiology of inflammatory bowel disease and to identify new therapeutic strategies for inflammatory bowel diseases such as Crohn’s disease or Ulcerative Colitis, along with complications derived from these diseases such as perianal fistules. Our group combines basic science with clinical studies for translational research with the aim of improving the quality of life of patients.

RESPONSIBLE

  • Dra. Carolina Serena Perelló

  • Presentation
  • Group members
  • Research lines
  • Competitive financing IP and equipment
  • Transfer
  • Publications
  • Dissemination
  • Contact

Inflammatory bowel disease (IMI), including Crohn’s disease and ulcerative colitis, is characterized by recurrent chronic intestinal inflammation. While the etiology of IIM persists to a great extent unknown, it implies a complex interaction between genetic, environmental or microbial factors and immune responses. A more in-depth knowledge of the pathophysiology of IIM may help to identify our therapeutic approaches to cure these maladies. Our group is especially interested in the relationship between the intestinal microbiota, the immunology and the mare adipose cells. The work in progress points out that the perilesional greix contributes to Crohn’s disease, and the translocation of intestinal bacteria that affect the perilesional greix and the interaction of the mare adipose cells and cells of the immune system in these maladies, ens allows to identify useful biomarkers for the diagnosis, prognosis or progression of malaltia.

  • Multi-omnic approach to the search for early predictive biomarkers of response to biological agents in Crohn’s disease.
  • Role of visceral fat in the pathophysiology of inflammatory bowel diseases.
  • New insights into the therapeutic aspect of adipose stem cells: implications for future stem cell therapies in inflammatory bowel disease.
  • Interaction between cellular and molecular mechanisms underlying the development of inflammatory bowel diseases.
  • Host-microbiome interactions: molecular mechanisms in inflammatory bowel diseases.

  • Títol del projecte: Ensayo clínico en Fase IIa para evaluar seguridad y eficacia del tratamiento con células troncales alogénicas mesenquimales derivadas de la grasa en pacientes con estenosis inflamatoria en el contexto de la Enfermedad de Crohn.

    IP: Loles Herreros Marcos

    Membre de l’equip: Carolina Serena

    Agència financiadora: ISCIII (Proyecto de Investigación Clínica Independiente)

    Financiació: 414.172 €.

    Duració (període de financiació): 01/01/2022-31/12/2024

    Expedient projecte: ICI21/0003

  • Títol del projecte: Succinato, un metabolito derivado de la microbiota, marcador de actividad en la Enfermedad de Crohn.

    IP: Margarita Menacho. Co-IP: Carolina Serena.

    Membres de l’equip: Diandra Monfort, Alicia Moliné, Gemma Valldosera.

    Agència financiadora I Beca Clínica GETECCU-Galápagos

    Financiació: 12.000€

    Duració (període de financiació): 01/01/2022-31/12/2022

    Expedient projecte: I Beca Clínica GETECCU-Galápagos

  • Títol del projecte: Peri-lesional adipose tissue (creeping fat) as an immune modulating element of intestinal dysbiosis in Crohn’s disease

    IP: Carolina Serena

    Membres de l’equip: Margarita Menacho, Aleidis Caro, Beatriz Espina.

    Agència financiadora ISCIII

    Financiació: 185.130 €.

    Duració (període de financiació): 01/01/2019-31/12/2022

    Expedient projecte: PI18/00037 (Proyectos de I+D+I en Salud)

  • Títol del projecte internacional: An integrative analysis of DNA methylation and RNA-Seq data in human adipose-stem cells of Crohn’s disease patients with different clinical activity

    IP: Carolina Serena.

    Membre de l’equip: Margarita Menacho

    Agència financiadora: European Crohn’s and Colitis Organization (ECCO).

    Financiació: 50.000 €.

    Duració (període de financiació): 01/01/2019-30/06/2020

    Expedient projecte: ECCO grant 2018 a Carolina Serena

    URL: https://www.ecco-ibd.eu/publications/ecco-news/committee-news/item/ecco-grant-study-synopsis-carolina-serena.html

  • Títol del projecte: A new probiotic strategy to improve metabolic and inflammatory profile in obese patients. SUCCIPRO.

    IP: Isabel Huber

    Membre de l’equip: Carolina Serena

    Agència financiadora Caixaimpulse. Fundación la Caixa.

    Financiació: 70.000 €.

    Duració (període de financiació): 01/01/2019-31/12/2021

    Expedient projecte: SUCCIPRO

  • Títol del projecte: Analyses of the global kinase activities in adipose tissue to find molecular differences resulting from insulin resistance across different clinical phenotypes from lean to obese and type 2 diabetic patients.

    IP: Joan Vendrell / Luis Fajas

    Membre de l’equip: Carolina Serena

    Agència financiadora: La Marató de TV3

    Financiació: 600.000 €.

    Duració (període de financiació): 01/01/2017-01/01/2020

    Expedient projecte: PV17013S

  • Títol del projecte: Mechanistic basis for the distinct inflammatory profile in obese and CD subjects: searching for novel therapeutic approaches

    IP: Carolina Serena.

    Membre de l’equip: Margarita Menacho

    Agència financiadora ISCIII

    Financiació: 159.000 €.

    Duració (període de financiació): 01/01/2016-30/06/2019

    Expedient projecte: PI15/00143 (Proyectos de I+D+I en Salud)

  • Títol del projecte: Antioxidant compounds in inflammation-related metabolic human diseases: in vitro and in vivo.

    IP: Carolina Serena.

    Agència financiadora MINECO

    Financiació: 40.000 €.

    Duració (període de financiació): 23/10/2014-23/10/2018

    Expedient projecte: RYC-2013-13186 (projecte associat al contrate Ramón y Cajal)

  • Títol del projecte: Identification of novel modulators of chronic inflammation in prevalent diseases: unveiling divergent mechanisms of disease (INFLAMES).

    IP: Antonio Zorzano / Joan Vendrell

    Membre de l’equip: Carolina Serena

    Agència financiadora ISCIII

    Financiació: 480.000 €.

    Duració (període de financiació): 01/01/2015-01/01/2018

    Expedient projecte: PIE14/00145 (Proyectos interciber)

  • S Fernández-Veledo; C Serena; J Vendrell; V Ceperuelo; E Calvo. PCT/EP2019/051157. Targeted interventions directed at reducing the levels of circulating succinate in a subject, and kits and method for determining effectiveness of said interventions. 17/01/2019. IISPV. WO/2019/141780

  • S Fernández-Veledo; C Serena; J Vendrell; A Zorzano. EP17382615.7. Methods for improving the cell therapy efficacy with mesenchymal stem cell populations. 18/09/2017. CIBERDEM.

    Year

    Smoking Suppresses the Therapeutic Potential of Adipose Stem Cells in Crohn’s Disease Patients through Epigenetic Changes

    Boronat-Toscano A, Vañó I, Monfort-Ferré D, Menacho M, Valldosera G, Caro A, Espina B, Mañas MJ, Marti M, Espin E, Saera-Vila A, Serena C. Cells. 2023; 12(7):1021. Impact factor: 7.666

    https://doi.org/10.3390/cells12071021

    The Genetic Diversity and Dysfunctionality of Catalase Associated with a Worse Outcome in Crohn’s Disease

    Iborra, M.; Moret, I.; Busó, E.; García-Giménez, J.L.; Ricart, E.; Gisbert, J.P.; Cabré, E.; Esteve, M.; Márquez-Mosquera, L.; García-Planella, E.; Guardiola, J.; Pallardó, F.V.; Serena, C.; Algaba-Chueca, F.; Domenech, E.; Nos, P.; Beltrán, B. The Genetic Diversity and Dysfunctionality of Catalase Associated with a Worse Outcome in Crohn’s Disease. Int. J. Mol. Sci. 2022, 23, 15881.

    https://doi.org/10.3390/ijms232415881

    Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn’s Disease

    Boronat-Toscano, A.; Monfort-Ferré, D.; Menacho, M.; Caro, A.; Bosch, R.; Espina, B.; Algaba-Chueca, F.; Saera-Vila, A.; Moliné, A.; Marti, M.; Espin, E.; Millan, M.; Serena, C. Int. J. Mol. Sci. 2022, 23, 11170. Impact factor: 6.208

    https://doi.org/10.3390/ijms231911170

    The Gut Microbiota Metabolite Succinate Promotes Adipose Tissue Browning in Crohn’s Disease

    Montfort-Ferré D, et al. 2022. (C. Serena* corresponding author).

    https://doi.org/10.1093/ecco-jcc/jjac069

    Glycogen accumulation in adipocyte precursors from elderly and obese subjects triggers inflammation via SIRT1/6 signaling. Índex d’impacte: 11.005

    Terrón-Puig M, et al. 2022.

    https://doi.org/10.1111/acel.13667

    Mn(II) Complexes of Enlarged Scorpiand-Type Azamacrocycles as Mimetics of MnSOD Enzyme. Applied Sciences. 12:2447. Índex d’impacte: 2.679

    Inclán M, et al. 2022.

    https://doi.org/10.3390/app12052447

    Crohn's Disease Increases the Mesothelial Properties of Adipocyte Progenitors in the Creeping Fat. Int J Mol Sci. Índex d’impacte: 5.923.
    Madeira A, Serena C, Ejarque M, Maymó-Masip E, Millan M, Navarro-Ruiz MC, Guzmán-Ruiz R, Malagón MM, Espin E, Martí M, Menacho M, Megía A, Vendrell J, Fernández-Veledo S. Crohn’s Disease Increases the Mesothelial Properties of Adipocyte Progenitors in the Creeping Fat. Int J Mol Sci. 2021 Apr 20;22(8):4292. PMID: 33924264; PMCID: PMC8074767.
    Protective properties of grape-seed proanthocyanidins in human ex vivo acute colonic dysfunction induced by dextran sodium sulfate. European Journal Nutrition. 60, pp.79-88. Índex impacte: 5.614
    González-Quilen C, Grau-Bové C, Jorba-Martín R, Caro-Tarragó A, Pinent M, Ardévol A, Beltrán-Debón R, Terra X, Blay MT. Protective properties of grape-seed proanthocyanidins in human ex vivo acute colonic dysfunction induced by dextran sodium sulfate. Eur J Nutr. 2021 Feb;60(1):79-88.  Epub 2020 Mar 18. PMID: 32189068.
    Point-of-care hepatitis C testing and treatment strategy for people attending Harm Reduction and Addiction Centres for hepatitis C elimination. J Viral Hepat; 00:1-4.
    Forns X, Colom J, García-Retortillo M, Quer JC, Lens S, Martró E, Domínguez-Hernández R, Casado MÁ, Buti M. Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination. J Viral Hepat. 2022 Mar;29(3):227-230. Epub 2021 Nov 29. PMID: 34806812; PMCID: PMC9299793.
    Adipose stem cells from patients with Crohn's disease show a distinctive DNA methylation pattern.Clin Epigenetics. Índex d’impacte: 6.551
    Serena C, Millan M, Ejarque M, Saera-Vila A, Maymó-Masip E, Núñez-Roa C, Monfort-Ferré D, Terrón-Puig M, Bautista M, Menacho M, Martí M, Espin E, Vendrell J, Fernández-Veledo S. Adipose stem cells from patients with Crohn’s disease show a distinctive DNA methylation pattern. Clin Epigenetics. 2020 Apr 6;12(1):53. PMID: 32252817; PMCID: PMC7137346.
    Gestational diabetes impacts fetal precursor cell responses with potential consequences for offspring. Stem Cells Transl Med. Índex d’impacte: 6.94
    Algaba-Chueca F, Maymó-Masip E, Ejarque M, Ballesteros M, Llauradó G, López C, Guarque A, Serena C, Martínez-Guasch L, Gutiérrez C, Bosch R, Vendrell J, Megía A, Fernández-Veledo S. Gestational diabetes impacts fetal precursor cell responses with potential consequences for offspring. Stem Cells Transl Med. 2020 Mar;9(3):351-363. Epub 2019 Dec 27. PMID: 31880859; PMCID: PMC7031647.
    Microbial Signature in Adipose Tissue of Crohn’s Disease Patients. Journal of Clinical Medicine. Índex d’impacte: 5.583
    Serena C, Queipo-Ortuño M, Millan M, Sanchez-Alcoholado L, Caro A, Espina B, Menacho M, Bautista M, Monfort-Ferré D, Terrón-Puig M, Núñez-Roa C, Maymó-Masip E, Rodriguez MM, Tinahones FJ, Espin E, Martí M, Fernández-Veledo S, Vendrell J. Microbial Signature in Adipose Tissue of Crohn’s Disease Patients. J Clin Med. 2020 Jul 31;9(8):2448. PMID: 32751800; PMCID: PMC7465250.
    Effects of Flavanols on Enteroendocrine Secretion. Biomolecules. 10-6, pp.844. ISSN 2218-273X. Índex d’impacte: 4.569
    Grau-Bové C, González-Quilen C, Terra X, Blay MT, Beltrán-Debón R, Jorba-Martín R, Espina B, Pinent M, Ardévol A. Effects of Flavanols on Enteroendocrine Secretion. Biomolecules. 2020 Jun 1;10(6):844. PMID: 32492958; PMCID: PMC7355421.
    Molecular Epidemiology Reveals Low Genetic Diversity among Cryptococcus neoformans Isolates from People Living with HIV in Lima, Peru, during the Pre-HAART Era. Pathogens. 9(8):665. Índex d’impacte: 3.492
    van de Wiele N, Neyra E, Firacative C, Gilgado F, Serena C, Bustamante B, Meyer W. Molecular Epidemiology Reveals Low Genetic Diversity among Cryptococcus neoformans Isolates from People Living with HIV in Lima, Peru, during the Pre-HAART Era. Pathogens. 2020 Aug 18;9(8):665. PMID: 32824653; PMCID: PMC7459599.
    Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. J Gastroenterol Hepatol. 35(9):1570-1578. Índex d’impacte: 4.029
    Rodríguez-Tajes S, Domínguez Á, Carrión JA, Buti M, Quer JC, Morillas RM, López C, Torras X, Baliellas C, Vergara M, Forner M, Zaragoza N, Salò J, Rigau J, Caballeria L, Mariño Z, Janè M, Colom J, Forns X, Lens S. Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. J Gastroenterol Hepatol. 2020 Sep;35(9):1570-1578. Epub 2020 Feb 4. PMID: 31957902.
    Current trends on access to treatment for hepatitis B in immigrants vs non-immigrants. Gastroenterology Report 8(5):362-366. Índex d’impacte: 3.651
    Miquel M, Pardo A, Forné M, Martínez-Alpin G, Rodríguez-Castellano A, Casas M, Rosinach M, Roget M, Dalmau B, Temiño R, Quer JC, Sanchez-Delgado J, Ortiz J, Vergara M. Current trends in access to treatment for hepatitis B in immigrants vs non-immigrants. Gastroenterol Rep (Oxf). 2020 Mar 27;8(5):362-366. PMID: 33163191; PMCID: PMC7603864.
    Adipose tissue mitochondrial dysfunction in human obesity is linked to a specific DNA methylation signature in adipose-derived stem cells. International journal of obesity. Índex d’impacte: 5.095
    Ejarque M, Ceperuelo-Mallafré V, Serena C, Maymo-Masip E, Duran X, Díaz-Ramos A, Millan-Scheiding M, Núñez-Álvarez Y, Núñez-Roa C, Gama P, Garcia-Roves PM, Peinado MA, Gimble JM, Zorzano A, Vendrell J, Fernández-Veledo S. Adipose tissue mitochondrial dysfunction in human obesity is linked to a specific DNA methylation signature in adipose-derived stem cells. Int J Obes (Lond). 2019 Jun;43(6):1256-1268. Epub 2018 Sep 27. PMID: 30262812; PMCID: PMC6760577.
    Keiran N, et al. 2019.
    Keiran N, Ceperuelo-Mallafré V, Calvo E, Hernández-Alvarez MI, Ejarque M, Núñez-Roa C, Horrillo D, Maymó-Masip E, Rodríguez MM, Fradera R, de la Rosa JV, Jorba R, Megia A, Zorzano A, Medina-Gómez G, Serena C, Castrillo A, Vendrell J, Fernández-Veledo S. SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity. Nat Immunol. 2019 May;20(5):581-592. Epub 2019 Apr 8. PMID: 30962591.
    EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. Therap Adv Gastroenterol. 21-12, pp.1-11. Índex d’impacte: 3.96
    Chaparro M, Barreiro-de Acosta M, Benítez JM, Cabriada JL, Casanova MJ, Ceballos D, Esteve M, Fernández H, Ginard D, Gomollón F, Lorente R, Nos P, Riestra S, Rivero M, Robledo P, Rodríguez C, Sicilia B, Torrella E, Garre A, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP; EpidemIBD study group of GETECCU. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. Therap Adv Gastroenterol. 2019 May 21;12:1756284819847034. PMID: 31205485; PMCID: PMC6535735.
    Differences between childhoodand adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Aliment Pharmacol Ther.49-4, pp.419-428. Índex d’impacte: 8.171
    Chaparro M, Garre A, Ricart E, Iglesias-Flores E, Taxonera C, Domènech E, Gisbert JP; ENEIDA study group. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Aliment Pharmacol Ther. 2019 Feb;49(4):419-428. Epub 2019 Jan 13. PMID: 30637837.
    Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res. 174:104694. Índex d’impacte: 5.970.
    Chen Q, Perales C, Soria ME, García-Cehic D, Gregori J, Rodríguez-Frías F, Buti M, Crespo J, Calleja JL, Tabernero D, Vila M, Lázaro F, Rando-Segura A, Nieto-Aponte L, Llorens-Revull M, Cortese MF, Fernandez-Alonso I, Castellote J, Niubó J, Imaz A, Xiol X, Castells L, Riveiro-Barciela M, Llaneras J, Navarro J, Vargas-Blasco V, Augustin S, Conde I, Rubín Á, Prieto M, Torras X, Margall N, Forns X, Mariño Z, Lens S, Bonacci M, Pérez-Del-Pulgar S, Londoño MC, García-Buey ML, Sanz-Cameno P, Morillas R, Martró E, Saludes V, Masnou-Ridaura H, Salmerón J, Quíles R, Carrión JA, Forné M, Rosinach M, Fernández I, García-Samaniego J, Madejón A, Castillo-Grau P, López-Núñez C, Ferri MJ, Durández R, Sáez-Royuela F, Diago M, Gimeno C, Medina R, Buenestado J, Bernet A, Turnes J, Trigo-Daporta M, Hernández-Guerra M, Delgado-Blanco M, Cañizares A, Arenas JI, Gomez-Alonso MJ, Rodríguez M, Deig E, Olivé G, Río OD, Cabezas J, Quiñones I, Roget M, Montoliu S, García-Costa J, Force L, Blanch S, Miralbés M, López-de-Goicoechea MJ, García-Flores A, Saumoy M, Casanovas T, Baliellas C, Gilabert P, Martin-Cardona A, Roca R, Barenys M, Villaverde J, Salord S, Camps B, Silvan di Yacovo M, Ocaña I, Sauleda S, Bes M, Carbonell J, Vargas-Accarino E, Ruzo SP, Guerrero-Murillo M, Von Massow G, Costafreda MI, López RM, González-Moreno L, Real Y, Acero-Fernández D, Viroles S, Pamplona X, Cairó M, Ocete MD, Macías-Sánchez JF, Estébanez A, Quer JC, Mena-de-Cea Á, Otero A, Castro-Iglesias Á, Suárez F, Vázquez Á, Vieito D, López-Calvo S, Vázquez-Rodríguez P, Martínez-Cerezo FJ, Rodríguez R, Macenlle R, Cachero A, Mereish G, Mora-Moruny C, Fábregas S, Sacristán B, Albillos A, Sánchez-Ruano JJ, Baluja-Pino R, Fernández-Fernández J, González-Portela C, García-Martin C, Sánchez-Antolín G, Andrade RJ, Simón MA, Pascasio JM, Romero-Gómez M, Antonio Del-Campo J, Domingo E, Esteban R, Esteban JI, Quer J. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res. 2020 Feb;174:104694. Epub 2019 Dec 16. PMID: 31857134.
    Importance of adherence to treatment with direct-acting antivirals in hepatitis C. Gastroenterol Hepatol. 1:14-19. Índex d’impacte: 11.382.
    Monte-Boquet E, Verdugo RM, Navarro H, Quer JC, Ventayol P. Importance of adherence to treatment with direct-acting antivirals in hepatitis C. Gastroenterol Hepatol. 2019 Sep;42 Suppl 1:14-19. English, Spanish. Epub 2020 Jun 16. PMID: 32560768.
    Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. The ISME journal. Índex d’impacte: 10.302
    Serena C, Ceperuelo-Mallafré V, Keiran N, Queipo-Ortuño MI, Bernal R, Gomez-Huelgas R, Urpi-Sarda M, Sabater M, Pérez-Brocal V, Andrés-Lacueva C, Moya A, Tinahones FJ, Fernández-Real JM, Vendrell J, Fernández-Veledo S. Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. ISME J. 2018 Jun;12(7):1642-1657. Epub 2018 Feb 12. PMID: 29434314; PMCID: PMC6018807.
    ERAS programs in elderly patients: is there a limit? Int J Colorectal Dis. 33-9, pp.1313.Índex d’impacte: 2.12
    Millan M, Espina-Perez B, Caro-Tarrago A, Jorba-Martin R. ERAS programs in elderly patients: is there a limit? Int J Colorectal Dis. 2018 Sep;33(9):1313. Epub 2018 Jul 12. PMID: 30003359.
    Angiopoietin-like protein 8/betatrophin as a new determinant of type 2 diabetes remission after bariatric surgery. Translational research: the journal of laboratory and clinical medicine. 184, pp. 35. Índex d’impacte: 7.012
    Ejarque M, Borlaug M, Vilarrasa N, Martinez-Perez B, Llauradó G, Megía A, Helland T, Gutierrez C, Serena C, Folkestad O, Nuñez-Roa C, Roche K, Casajoana A, Fradera R, González-Clemente JM, López M, Mohn AC, Nedrebø BG, Nogueiras R, Mellgren G, Fernø J, Fernández-Veledo S, Vendrell J. Angiopoietin-like protein 8/betatrophin as a new determinant of type 2 diabetes remission after bariatric surgery. Transl Res. 2017 Jun;184:35-44.e4. Epub 2017 Mar 9. PMID: 28347650.
    Crohn’s disease disturbs the immune properties of human adipose-derived stem cells related to inflammasome activation. Stem Cell Reports. 9:1 - 15. Índex d’impacte: 7.765
    Serena C, Keiran N, Madeira A, Maymó-Masip E, Ejarque M, Terrón-Puig M, Espin E, Martí M, Borruel N, Guarner F, Menacho M, Zorzano A, Millan M, Fernández-Veledo S, Vendrell J. Crohn’s Disease Disturbs the Immune Properties of Human Adipose-Derived Stem Cells Related to Inflammasome Activation. Stem Cell Reports. 2017 Oct 10;9(4):1109-1123. Epub 2017 Sep 28. PMID: 28966116; PMCID: PMC5639166.
    Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. American Journal of Gastroenterology. 112-1, pp.120-131. Índex d’impacte: 10.864
    Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. Am J Gastroenterol. 2017 Jan;112(1):120-131. Epub 2016 Dec 13. PMID: 27958281.

Team Members

  • Group leader

    • Dra. Carolina Serena Perelló

  • Clinical researchers

    • Aleidis Caro
    • Margarita Menacho
    • Jc Quer
    • Beatriz Espina
    • Gemma Valldosera
    • Carme Abadia
    • Lidia Cabrinety
    • M. José Mañas

  • PhD students

    • Diandra Monfort
    • Albert Boronat

  • Advanced practice nurses at the Hospital Joan XXIII in Tarragona

    • Alicia Moliné
    • Mai Lahoz

  • Research technician

    • Irene Vaño
    • Nicolás Moreno

Altres grups de Infection, Immunity and Environment

See all